Key Insights

Highlights

Treatment Research

2 treatments under study, led by Methotrexate 03 Mgkgweek To A Maximum And Optimal Dose Of 25 Mgweek

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT00349674Phase 3UnknownPrimary

WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides

Showing all 1 trials

Research Network

Common Treatments

  • Methotrexate 03 Mgkgweek To A Maximum And Optimal Dose Of 25 Mgweek1
  • Azathioprine 2 Mgkgday1

Active Sponsors

  • Hospices Civils de Lyon1

Top Investigators

Activity Timeline